Fulgent Genetics, INC Form 4 insider transactions

Fulgent Genetics CFO and Treasurer Paul Kim reported the disposition of 1,131 shares of common stock on June 1, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 754 shares of common stock on June 2, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Jian Xie, President and COO of Fulgent Genetics, Inc., reported the sale of 1,135 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Jian Xie, President and COO of Fulgent Genetics, Inc., sold 1,873 shares of common stock on May 27, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported the disposition of 1,837 shares of common stock across two transactions in late May 2025, primarily to satisfy tax withholding obligations related to vested restricted stock units.

Fulgent Genetics, Inc. CEO Ming Hsieh reported the disposition of 5,060 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, reported the sale of 1,039 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Director Linda Marsh reported the acquisition of restricted stock units and the disposal of common stock in Fulgent Genetics, Inc.

Director Michael Nohaile reports acquisition and disposal of Fulgent Genetics stock and stock options.

Director Regina E. Groves acquired 8,982 shares of Fulgent Genetics, Inc. on May 15, 2025, through restricted stock units.

Fulgent Genetics CEO Ming Hsieh reports disposition of shares to cover tax obligations and details beneficial ownership through trusts and minor accounts.

Chief Scientific Officer of Fulgent Genetics, Gao Hanlin, reports disposition of shares to cover tax obligations.

Jian Xie, President and COO of Fulgent Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

CFO of Fulgent Genetics, Paul Kim, reports disposition of shares to cover tax obligations from vesting restricted stock units.

Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, reports a transaction involving common stock to cover tax obligations.

Fulgent Genetics' CFO and Treasurer, Paul Kim, purchased 100,000 shares of the company's common stock at an average price of $15.9647 on March 5, 2025.

Jian Xie, President and COO of Fulgent Genetics, reports a transaction involving common stock related to tax withholding obligations and holdings in a family trust.

Jian Xie, President and COO of Fulgent Genetics, files an amended SEC Form 4 to correct transaction dates related to tax withholding obligations on vested restricted stock units.

CFO and Treasurer of Fulgent Genetics, Paul Kim, reports disposition of shares to cover tax obligations arising from vesting of restricted stock units.

Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, reports disposition of shares to cover tax obligations.

CFO and Treasurer of Fulgent Genetics, Paul Kim, reports the acquisition and disposal of company stock related to the vesting of performance-based and regular restricted stock units (RSUs), with shares withheld to cover tax obligations.

Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, reports the acquisition and disposal of company stock related to the vesting of performance-based and regular restricted stock units, along with shares withheld for tax obligations.

Jian Xie, President and COO of Fulgent Genetics, reports acquisition and disposal of common stock due to vesting of restricted stock units and tax withholding obligations.

Fulgent Genetics CEO Ming Hsieh reports acquisition and disposal of company stock related to vesting of performance-based and restricted stock units, as well as tax withholding obligations.

Jian Xie, President and COO of Fulgent Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Fulgent Genetics' CEO, Ming Hsieh, sold shares to satisfy tax obligations related to vested restricted stock units.

Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Fulgent Genetics CFO Paul Kim reports the withholding of shares to cover tax obligations arising from the vesting of restricted stock units.

Fulgent Genetics CEO Ming Hsieh reports disposition of shares to cover tax obligations and details beneficial ownership through various trusts and custodial accounts.

Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, reports a transaction involving the withholding of shares to cover tax obligations.